WO1997026534A1 - Detection de la necrose du muscle cardiaque a l'aide d'immunodosages et d'anticorps appropries a cet effet - Google Patents

Detection de la necrose du muscle cardiaque a l'aide d'immunodosages et d'anticorps appropries a cet effet Download PDF

Info

Publication number
WO1997026534A1
WO1997026534A1 PCT/FI1997/000016 FI9700016W WO9726534A1 WO 1997026534 A1 WO1997026534 A1 WO 1997026534A1 FI 9700016 W FI9700016 W FI 9700016W WO 9726534 A1 WO9726534 A1 WO 9726534A1
Authority
WO
WIPO (PCT)
Prior art keywords
troponin
measurement
complex
antibody
serum
Prior art date
Application number
PCT/FI1997/000016
Other languages
English (en)
Inventor
Alexei Katroukha
Jarkko Eskola
Eugenii Severin
Sergey Severin
Timo Korpela
Original Assignee
Finnish-Russian Joint Biotechnology Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Finnish-Russian Joint Biotechnology Laboratory filed Critical Finnish-Russian Joint Biotechnology Laboratory
Priority to EP97901090A priority Critical patent/EP0965043B1/fr
Priority to DE69711937T priority patent/DE69711937T2/de
Publication of WO1997026534A1 publication Critical patent/WO1997026534A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein

Definitions

  • This invention relates to clinical diagnostics and more particularly to the diagnostics and therapy follow-up of heart muscle necrosis.
  • the invention concerns with a new approach to monitor the condition of heart by leakage of two proteins, troponin I and C, from necrotic heart muscle.
  • Heart infarction is one of the commonest causes of death of adult persons in developed countries. In case there is available quick diagnosis after infarction followed by appropriate medicinal treatment or surgical operation, a significant part of the patients can be rescued.
  • the required laboratory diagnostics is traditionally based on the detection of elevated enzyme activities of e.g. creatinine kinase (CK) , lactate dehydrogenase (LD) , or aspartate a inotran erase (GOT) in serum.
  • CK creatinine kinase
  • LD lactate dehydrogenase
  • GOT inotran erase
  • the drawback is, however, the ambiguousness of interpreting the results since the enzymes can also originate from organs other than heart.
  • the diagnostics of the acute myocardial infarction (AMI) is to be based on the laboratory tests accompanied with rather diffuse clinical symptoms or on electrocardiography (ECG).
  • the building block proteins of the heart muscle contractile apparatus have been subject of intensive studies for their applicability to the heart infarction diagnostics (F.C. Apple: Laboratory Medicine, May 1992, Vol. 23, No. 5, pp. 311-317).
  • the troponins are proteins located on the thin film filament of the muscle contractile apparatus. There are three troponins (Tns), troponin T (tropomyosin-binding subunit with molecular mass of 39kD), Tn I (actomyosin- adenosine triphosphatase-inhibiting subunit with molecular mass of 26.5kD), and Tn C (calcium-binding subunit with molecular mass of 18kD), acting together to regulate the muscle contraction.
  • the heart Tns, excluding Tn C are immunologically different from those in skeletal muscle. This forms the grounds of utilizing troponins as specific markers of heart muscle damages.
  • Tn C is not suitable for heart diagnostics at all since the slow-twitch skeletal isoform of Tn C is identical to the cardiac isoform.
  • Tn I also exists in cardiac, fast- twitch and slow-twitch skeletal isoforms.
  • the cardiac isoform of Tn I is about 40% dissimilar from the skeletal isoform and contains an additional specific functional amino acid sequence on the N-terminus. Despite of the instability of Tn I, it is considered as such one of the most promising markers of the cardiac injury (SCRIPPS NEWS, CA, USA, 1993, Vol. 7, No.2.).
  • the object of this invention is an improved method for determination of the status of cardiac muscle necrosis by immunoassay comprising of simultaneous determination of two cardiac muscle troponins I and C (Tn I and Tn C), able to bind to each other to form a complex I-C.
  • the invention exploits the observation that variable portion of Tn I in serum is complexed with Tn C.
  • the complexed Tn I (I-C) and Tn I - complexable to externally added Tn C (total Tn I-C), or the ratio Tn I-C/total Tn I-C, can be used as an improved measure for heart infarction diagnostics.
  • FIG. 1 Gel chromatography of Tn I added to a normal serum and of a serum of a patient with acute myocardial infarction (AMI) on a column separating proteins according to their molecular masses from 10,000 to 1 million daltons (calibration points with known protein standards indicated) .
  • AMI acute myocardial infarction
  • FIG. 2 Gel electrophoresis pattern of Tns C, I, and T on gradient polyacrylamide gel (10-20% acrylamide).
  • Figure 2 shows that Tn I exists in serum of AMI patients in a complex mainly with Tn C.
  • FIG. 3 Analysis of normal serum and three sera from suspected AMI patients (AMI Sample 1-3) by using different monoclonal antibodies.
  • NHS refers to Normal Human Serum.
  • FIG 4 Figure 4 shows that when pure Tn I is added to normal serum (all-male serum) the signal increases indicating that normal serum pool contains Tn C. External Tn C increases signal dramatically whenever Tn C is detected with a labeled Tn C-specific antibody (here clone 1A2).
  • SA refers to Streptavidin coated onto a microtiter plate surface and B to Biotin.
  • FIG. 5 Mesurement of Tn I-C complex in sera of 11 potential AMI patient after hospital admission by a sandwich assay (coating antibody 8E10 and labeled antibody 1A2). Black bars refer to Tn I-C and grey bars to total Tn I-C complex obtained by adding Tn C (1 ⁇ g/microtiter plate well) .
  • Figure 7 Variation of signal from Tn I (10F4 coating, 7F5 labeled) and Tn I-C (8E10 coating, 1A2 labeled) as a function of time in sera of AMI patients.
  • Table I Correlation coefficient between measurement of troponin I (by methods II and 12), Tn I-C, total Tn I-C, CK, and CKB.
  • Troponins T, I, and C are immobilized together as a group in the muscle contractile apparatus.
  • Troponin T is found to contain an unbound cytosolic pool of 6% of total myocardial Tn T content. Washout of this pool from muscle cells may cause the peak of Tn T concentrations in serum on the first day of early reperfusion of the infarct zone. There is a rapid disappearance of Tn I from myofibrils during myocardial infarction but Tn T was shown to persist in the zone nearly unaltered for six days. The degradation rate of Tn T is comparable to that of myosin light chains.
  • the difference in the disappearances of Tns I and T from myofibrils may account for the differences in the release kinetics of both markers in patients with nonperfused myocardial infarction.
  • the continuous degradation of myofibrils during infarct evolution and healing results in a resistant egress of myofibril components into circulation (Katus, H.A., et al. in Laboratory Medicine, Vol. 23, 1992, p.312) .
  • Tn C is not considered useful as the marker of myocardial infarction
  • Tn I is for a long time considered as one of the most promising specific markers.
  • Tn I in serum of AMI patients exists as a complex of Tn I with Tn C (Tn I-C) bound with other proteins and this Tn I-C is used for heart infarction diagnostics either as such or so that external Tn C is added (total I-C). Additional advantages are obtained from concomitant stabilization of Tn I by Tn C and in this way Tn I content in serum is standardized resulting in a more accurate and reproducible measure for the infarction.
  • Scheme 1 illustrates the principal reactions which the present invention is based onto.
  • Tns According to their biological function, the molecular conformations of each Tns and their mutual interaction change considerably during the contraction and release of muscle tension. Concomitantly the immunological properties of Tns and especially that of Tn I shall be different when it is free or bound to Tn C. If the sample contains both free Tn I and complex Tn I-C, the primary antibody binds different portion of free Tn I and Tn I-C complex. It is shown in this invention that individual patient samples contain f irly different ratios of free and complexed Tn I. Thus, the measurement of only Tn I does not necessarily probe the real amount of Tn I.
  • Tn I contains hydrophobic areas in the molecule that cause its strong nonspecific binding to various materials including glass and plastics. This area locates most probably at the Tn I-C interface or the Tn I-C interaction otherwise affects occurrence of such areas. Since different serum samples contain different ratio of Tn I-C/ total Tn I-C contents, and since the determination of exact nonspecific binding background in the signal is tedious, it is highly desirable to stabilize the serum samples in the respect of these background effects. In conclusion, the ratio Tn I-C /total Tn I-C includes considerably more information about the history and degree of damage of the heart infarction than measurement of Tn I.
  • Tn I is very unstable molecule in serum and in other solutions. Its immunological activity decreases to 20% within one hour at 37°C.
  • Tn I assays a related stabilization as with the cited Tn I standard preparation above, is exploited for increasing the reproducibility and sensitivity of Tn I assays.
  • Such external Tn C can originate from any source including those produced in microbes by the recombinant techniques.
  • the stabilization also provides an additional advantage since the clinical samples may be stored for an undetermined periods before the measurement.
  • Such stabilization can be carried out by adding Tn C into blood sampling tube, to serum, or to a sample to be analyzed.
  • the antibodies mentioned in this invention refer to those found in the catalogs of Hytest Ltd., Turku, Finland or BioSpacific Ltd, California, USA.
  • FIG. 1 shows that any of the Tns does not exist in the serum in free form but are bound to other biomolecules and usually separated into two fractions in the chromatographic conditions. Also pure Tn I added to normal serum, not containing heart-originated proteins, rapidly form the aggregates .
  • FIG. 2 shows that when Tns I, C, and T are captured by an immunoaffinity adsorbent from serum pool of AMI patients, followed by washing and eluting out of the adsorbent at low pH, only a complex containing of Tns I and C are detected. Thus Tn T does not significantly bind to Tn I-C.
  • FIG. 2 shows pure standard Tns, I, C, and T specifically detected on an electrophoresis gel.
  • the three lanes left side represents electrophoresis of a sample of a serum from a pool of AMI patients also specifically detected by Tn I, Tn C, and Tn T -specific antibodies.
  • the serum from AMI patients was first applied on an immunoaffinity column of Sepharose 4 B CL derivatized with monoclonal antibody known to bind the complex Tn " T-I-C. This fraction was eluted from the column and subjected to the electrophoresis followed by the Western blotting.
  • the membrane was allowed to react with specific mice antibodies against each individual Tn forms and stained thereafter with goat anti-mouse IgG labeled with horseradish peroxidase which was detected by chemiluminescence.
  • the bands at the molecular masses at 55 and 25 kD originate from the heavy and light chains of the mouse antibodies used to capture the complex Tn I-C-T being partly detached from the affinity column by the acid eluent.
  • Figure 3 characterizes the test system of the present invention by different antibodies.
  • the secondary labeled antibody (7F5) was specific to Tn I.
  • the low signals with anti-Tn T antibody (1C11) as the primary catching antibody indicates that Tn T is not involved in complex with Tn I whereas anti-Tn C antibodies (1A2 and 7E4) yield remarkable signals.
  • the antibody 10F4 is not strictly specific to Tn I but preferably recognizes Tn I in complex I-C.
  • FIG 4 shows that serum pool of healthy blood donator men (all-male serum) contains Tn C which can be found and quantitated in the serum by adding Tn I purified from human heart. This proves that Tn C itself is a poor marker of heart muscle damages. If the catching antibody for Tn I is omitted in the test system, the background signals from the secondary, labeled antibody (1A2 specific to Tn C) are small and are even decreased by adding Tn I in concentration of 30 ng/ml (black bar in Figure 4 b). If Tn C is added into the same system, the background due to adsorption of Tn C onto the microtiter plate surface is slightly increased (grey bar in Figure 4 b) while addition of Tn I decreases it (black bar).
  • Tn I catching antibody is immobilized and pure Tn I (30 ng/ml) is added into normal serum (black bar). Since the background (grey bar) is small, and the other background controls are valid (see before), the normal serum contains Tn C If a large excess of Tn C is added into the system similar to Figure 4 c, the signal increase (black bar) is dramatic while the background keeps still relatively small (Figure 4 d) .
  • Figure 5 exemplifies the effects of externally added Tn C into serum samples of 11 potential AMI patients with high CK values .
  • the signal increased by adding Tn C into the system being attributable to the additional formation of complex Tn I-C.
  • the increase is not constant but considerably varies from patient to patient.
  • the signal without addition of Tn C (Tn I-C complex in the serum; grey bars) compared to the signals after adding Tn C in excess (total Tn I-C, black bars) are around 75% in the average. This value can change accordingly with the experimental conditions.
  • Free Tn C originating from skeletal muscle may interfere with the values obtained for Tn I-C complex from heart in the system similar to Figure 5, where Tn I is captured by heart-specific antibody.
  • the situation can be illustrated by two patients, one having heart attack after physical exercise and the other one without it. Both are assumed to have equal size of the necrotic zone. After the physical exercise free Tn C leaked from skeletal muscles, shall stabilize the Tn I leaking from heart and thus the increase by addition of external Tn C into such serum will be less than with the other one.
  • the patient withcut Tn C leakage from skeletal muscle may have lower levels of measurable Tn I since it can have been reversibly denatured in the lower " concentrations of stabilizing Tn C leaking from heart muscle only. However, in the latter case the signal increase within adding external Tn C can be considerably higher.
  • the determination pf Tn I-C and total Tn I-C values can yield extra information about the condition of the patient.
  • Table 1 shows results obtained by statistical treatment of the correlation coefficients of diagnostic results randomly chosen among AMI patients taken into hospital. It shows that correlation coefficients are usually highest in the cases the total Tn I-C, or when complex Tn I-C, or when Tn I-C (marked I+IC in Table 1) is measured by two labeled antibodies, one preferably binding to Tn C and the other one to Tn I.
  • Total Tn I-C complex shows the best correlation to CK and CKB while only poor correlation occurs with the methods where CK and CKB are compared with Tn I measured by two different sandwich assays with two antibodies against Tn I (marked II : 7F5 coating, 10F4 labeled; and 12 : 8E10 coating, 7F5 labeled).
  • Figure 6 shows that generally there is a correlation between Tn I and complex Tn I-C but at early and late stages after hospital admission there appear large variations from the regression line. It is noticeable that this effect can be utilized to evaluate the history of infarction.
  • Figure 7 illustrates further the advantages of this invention by showing that the time-courses of the increase of the signal from Tn I (dashed line with using antibodies 10F4, 7F5) and complex Tn I-C (solid line with using antibodies 8E10, 1A2) are related in form but the signal from Tn I-C is much higher thus providing considerably higher sensitivity of the assay or earlier diagnosis.
  • Figure 8 shows that addition EDTA increases the signal when the complex Tn I-C is detected by antibody pairs 10F4 and 1A12 (coating and labeled, respectively). Since the antibody 1A12 binds to Tn I and the signal from it increases by adding EDTA, the epitope of this antibody must situate near the mutual binding site of Tn I and Tn C. This provides another route to measure the total Tn I-C.
  • An additional advantage of the present invention is achieved by measuring the ratio of the complex Tn I-C in the presence or absence of EDTA or another complexing agent such as EGTA, DTPA, or citrate. Such treatment will destroy the Tn I-C complex as described in the British Patent
  • the main embodiment of the present invention is that while Tn C is not useful for heart infarction diagnostics for its unspecificity, as such, it can be exploited indirectly for such diagnostics in the following ways: 1) by exploiting the observation that a considerable, but largely variable, portion of Tn I exists as a complex with Tn C in serum of AMI patients and by utilizing the ratio Tn I-C / total Tn I-C or Tn I-C - complexable with Tn C as a measure for heart muscle necrosis, 2) by stabilizing Tn I from denaturation with an external Tn C added into the sample, 3) by standardizing the signal/background ratio in different serum samples by driving Tn I totally to the stable complex Tn I-C, 4) by measuring the ratio Tn I-C/ Tn C - detachable from the complex Tn I-C, by measuring Tn I with and without addition of a strong complexing agent, such as EDTA in the serum sample, 5) by measuring simultaneously Tn I-C and total Tn I-
  • Troponin C is labeled with label 2.
  • Labels 1 and 2 are preferably measured simultaneously at different wavelengths enabling to get the ratio Tn I-C / total Tn I-C in the same condition.
  • the first and second labels can be other detectable molecule such as different enzymes, radioactive atoms, luminescence molecules, or fluorescing molecules with different wavelengths of detection.
  • the complex Tn I-C can be also measured by a competitive assay where a labeled Tn I-C is added into a sample and a competition for the sample Tn I-C with the labeled Tn I-C is created.
  • the binding antibody for the complex can be prepared from a polyclonal antibody through a proper fractionation procedure or by preparing a specific monoclonal antibody.
  • N 1 -(p-isothiocyanatobenzyl)-diethylenetriamine-N 1 ,N 2 ,N 3 ,N 3 - tetraacetic acid europium complex (DTTA) (Wallac, Turku, Finland) in a 60-fold mplar excess is allowed to react with the appropriate antibody at pH 9.8 overnight.
  • the labeled antibody is separated from excess of DTTA on a column of Sephadex G-50 (1x5 cm) and Sepharose 6 B (1x50 cm) by using 50 mmol/L Tris-HCl buffer, pH 7.8, containing 9 g/L of NaCl and 0.05 % NaN 3 as the eluting agent (TSA buffer).
  • TSA buffer Tris-HCl buffer
  • Bovine serum albumin (1 g/L) is used as stabilizer in the solution.
  • the monoclonal antibody in concern (for example, 8E10) is allowed to react with 20-molar excess of an isothiocyanato- phenyl derivative of trioxyethylene-amidibiotin (SCN- biotin) in 50 mmol/L sodium carbonate buffer, pH 9.8, for 2 h at the room temperature.
  • the final concentration of the antibody in 1 mL of reaction mixture shall be around 1 mg/mL (described in ref. Hemmila I, Heikkila J, Leivo P. Direct and indirect immunofluorometry of thyrotropin [Abstract 671].Clin Chem 1989; 35:1206).
  • biotinylated antibody is separated from the reaction mixture by gel filtration using NAP-10 and PD-10 disposable columns (Pharmacia, Uppsala, Sweden) using TSA buffer as the eluent.
  • Bovine serum albumin (1 g/L) is used as stabilizer in the solution .
  • Tn I or Tn I-C The time-resolved assay of Tn I or Tn I-C is performed with the streptavidine-coated microtiter wells (Wallac, Turku, Finland).
  • Total Tn I-C assay is performed essentially similarly as Tn I and Tn I-C assays .
  • Patient serum samples or standards prepared in normal human serum
  • Biotinylated catching antibody 300 ng/well
  • Eu-labeled antibody 200 ng/well and in the case of measurement of total Tn I-C, Tn C 50 -2000 ng/well are added in TSA buffer containing 0.1 % bovine serum albumin (Wallac, Turku, Finland).
  • the final reaction volume is 100 ⁇ L. After incubation for 1 h with gentle agitation at the room temperature, the strip wells are washed six times with Wash solution and 200 ⁇ L of Enhancement solution/well (Wallac, Turku, Finland) are added. After 5 min incubation with shaking and after a further 10 min without shaking the fluorescence is measured with a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
  • Microtiter plates are coated by with an antibody (10F4, Hytest, Turku, Finland) in 50 mmol/l sodium carbonate buffer, pH 9.2, at a concentration of 10 ⁇ g /mL overnight.
  • the plate wells are washed six times with a wash solution (Labmaster Ltd., Turku, Finland) and saturated with bovine serum albumin.
  • the secondary antibody (1A12, Bios Pacific, USA) is labeled with europium chelate according to the instructions from the manufacturer (Wallac Ltd., Turku, Finland).
  • the assay is carried out by adding 25 ⁇ L serum to the coated well and then 75 ⁇ L of assay buffer (Labmaster Ltd.) containing either 10 mM EDTA or not.
  • the wells are washed six times with the wash solution (Labmaster Ltd., Turku, Finland) and then the labeled antibody (200 ng/well) is added in the volume of 100 ⁇ L in the assay buffer (Labmaster Ltd. ) .
  • the wells are washed six times with the washing solution and 200 ⁇ L of Enhancement Solution (Wallac Ltd., Turku, Finland) is added and the fluorescence is measured after 10 minutes with a gentle shaking of the plate.
  • Tn C is immobilized into the cyanogen bromide activated agarose according to the manufacturer's instructions (Pharmacia, Uppsala, Sweden) by using 1 mg of Tn C per ml of moist activated gel. Similar gel is prepared for Tn I.
  • the crude antibody solution (1 mL ascites fluid) is eluted through both 1-mL columns in buffered (pH 7.8) physiological salt solution.
  • the proteins eluted through the both columns are adsorbed onto an immobilized Tn I where Tn C is allowed to complex (Tn I-C column).
  • Tn I-C column The protein obtained from Tn I-C column is coated onto a microtiter plate by passive adsorption (Tienhaara et al., Clin.Chem. (1990), 36/11, 1961) (100 ⁇ g/well, overnight) and the wells are washed six times with a Wash solution (Wallac Ltd., Turku, Finland). Tn I-C complex is labeled with europium chelate (Wallac Ltd., Turku, Finland) as the antibody in Example 1. Sample with a constant known amount of labeled Tn I-C are added in the assay buffer (Wallac Ltd., Turku, Finland) into the microtiter wells as in Example 1. The incubations, washings, and measurements are thereafter performed essentially as in Example 1. The content of Tn I-C is inversely proportional to the signal obtained from labeled Tn I-C.
  • Tn I-C The assay of Tn I-C is performed as described in Example 1 until the second labeled antibody specific to Tn C (e.g. 1A2) is added into the reaction mixture and incubated and washed six times. After this procedure a new reaction is carried out in the same wells within the reaction mixture with another labeled antibody, such the antibody 7F5 which binds to another epitope than the primary antibody on Tn I, or Tn C is labeled with another lanthanide chelate than europium; such as samarium, terbium, or yttrium.
  • This labeling reaction can be performed essentially as the one with the europium chelate as described in Example 1 or in reference, Pettersson et al., (1992) Clin.Chem.
  • both labeled antibodies are added in the same time and measured with a time-resolved fluorometer (wallac Ltd., Turku, Finland) within the Enhancement solution by fluorescence at the different wavelengths from the separate metal ions.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à une méthode de diagnostic permettant de déterminer la nécrose du muscle cardiaque et consistant à mesurer dans le sang, à l'aide d'un immunodosage, le niveau du complexe I-C de la troponine spécifique du coeur. Cette méthode consiste (1) à incuber un échantillon de plasma ou de sérum avec un anticorps primaire spécifique de la troponine I, C ou I-C, (2) à séparer l'immunocomplexe formé comprenant l'anticorps primaire ainsi que la troponine I-C, et (3) à mesurer le taux de l'immunocomplexe isolé au moyen d'un second anticorps marqué (anti-troponine I, anti-troponine C, ou anti-troponine I-C), de manière à ce qu'une éventuelle contribution provenant seulement de troponine I ou C séparée ne soit pas mesurée. Dans un autre mode de réalisation, lorsque l'anticorps primaire est seulement spécifique de I-C, on peut aussi mesurer l'immunocomplexe formé par I-C marqué de manière compétitive.
PCT/FI1997/000016 1996-01-15 1997-01-14 Detection de la necrose du muscle cardiaque a l'aide d'immunodosages et d'anticorps appropries a cet effet WO1997026534A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97901090A EP0965043B1 (fr) 1996-01-15 1997-01-14 Detection de la necrose du muscle cardiaque a l'aide d'immunodosages et d'anticorps appropries a cet effet
DE69711937T DE69711937T2 (de) 1996-01-15 1997-01-14 Entdecken von nekrosen des herzmuskels durch einen immunoassay und entsprechende antikorper

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI960167 1996-01-15
FI960167A FI104857B (fi) 1996-01-15 1996-01-15 Sydänlihaksen soluvaurioiden asteen mittaus immunokemiallisella menetelmällä sisältäen menetelmään soveliaat vasta-aineet

Publications (1)

Publication Number Publication Date
WO1997026534A1 true WO1997026534A1 (fr) 1997-07-24

Family

ID=8544843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI1997/000016 WO1997026534A1 (fr) 1996-01-15 1997-01-14 Detection de la necrose du muscle cardiaque a l'aide d'immunodosages et d'anticorps appropries a cet effet

Country Status (4)

Country Link
EP (1) EP0965043B1 (fr)
DE (1) DE69711937T2 (fr)
FI (1) FI104857B (fr)
WO (1) WO1997026534A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029726A2 (fr) * 1996-12-27 1998-07-09 Coulter International Corp. Procede de detection de la troponine i et de determination de sa concentration totale dans un echantillon biologique
WO1999031235A1 (fr) * 1997-12-18 1999-06-24 Spectral Diagnostics, Inc. Polypeptides a chaine unique comprenant la troponine i et la troponine c
US7078486B2 (en) 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
US20090233268A1 (en) * 2008-03-05 2009-09-17 Axela Inc. Detection of biomarkers and biomarker complexes
US9285362B2 (en) 2006-10-18 2016-03-15 Axela, Inc. Measuring multiple analytes over a broad range of concentrations using optical diffraction
CN109239031A (zh) * 2018-09-10 2019-01-18 吉林大学 建立时间分辨荧光免疫层析法检测mybpc3试剂盒
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405249A1 (de) * 1993-02-23 1994-08-25 Pasteur Sanofi Diagnostics Stabilisierte Troponin-Zubereitung für Immunoassays und Verfahren zur Stabilisierung von Troponin für Immunoassays
WO1996033415A1 (fr) * 1995-04-18 1996-10-24 Biosite Diagnostics Incorporated Nouveaux procedes de dosage de la troponine i et t et de ses complexes, et selection d'anticorps utilises dans des dosages immunologiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405249A1 (de) * 1993-02-23 1994-08-25 Pasteur Sanofi Diagnostics Stabilisierte Troponin-Zubereitung für Immunoassays und Verfahren zur Stabilisierung von Troponin für Immunoassays
WO1996033415A1 (fr) * 1995-04-18 1996-10-24 Biosite Diagnostics Incorporated Nouveaux procedes de dosage de la troponine i et t et de ses complexes, et selection d'anticorps utilises dans des dosages immunologiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LABORATORY MEDICINE, Volume 23, No. 5, May 1992, HUGO A. KATUS et al., "Proteins of the Troponin Complex", page 311. *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029726A2 (fr) * 1996-12-27 1998-07-09 Coulter International Corp. Procede de detection de la troponine i et de determination de sa concentration totale dans un echantillon biologique
WO1998029726A3 (fr) * 1996-12-27 1999-01-28 Coulter Int Corp Procede de detection de la troponine i et de determination de sa concentration totale dans un echantillon biologique
WO1999031235A1 (fr) * 1997-12-18 1999-06-24 Spectral Diagnostics, Inc. Polypeptides a chaine unique comprenant la troponine i et la troponine c
US7078486B2 (en) 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
US9285362B2 (en) 2006-10-18 2016-03-15 Axela, Inc. Measuring multiple analytes over a broad range of concentrations using optical diffraction
US20090233268A1 (en) * 2008-03-05 2009-09-17 Axela Inc. Detection of biomarkers and biomarker complexes
US8338189B2 (en) * 2008-03-05 2012-12-25 Axela Inc. Detection of biomarkers and biomarker complexes
US8877516B2 (en) 2008-03-05 2014-11-04 Axela, Inc. Detection of biomarkers and biomarker complexes
US10670611B2 (en) 2014-09-26 2020-06-02 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN109239031A (zh) * 2018-09-10 2019-01-18 吉林大学 建立时间分辨荧光免疫层析法检测mybpc3试剂盒

Also Published As

Publication number Publication date
DE69711937T2 (de) 2002-08-22
EP0965043A1 (fr) 1999-12-22
FI104857B (fi) 2000-04-14
EP0965043B1 (fr) 2002-04-10
FI960167A (fi) 1997-07-16
DE69711937D1 (de) 2002-05-16
FI960167A0 (fi) 1996-01-15

Similar Documents

Publication Publication Date Title
CN1759319B (zh) 生物液中肾上腺髓质素原中间区域部分肽在制备免疫诊断剂中的用途
CA2008360A1 (fr) Essai immunologique pour le diagnostic de l'infarctus du myocarde
JP2000509486A (ja) １段階オールインワン乾燥試薬イムノアッセイ
JP2517187B2 (ja) アナライト変異体分析
Roxin et al. Radioimmunoassays of human myoglobin in serum and urine
EP0965043B1 (fr) Detection de la necrose du muscle cardiaque a l'aide d'immunodosages et d'anticorps appropries a cet effet
US20030124616A1 (en) Homocysteinylated transthyretin
EP1169647B1 (fr) Procede d'analyse de la quantite de tissu adipeux intra-abdominal
Cozzi et al. Development of an immunoassay for all human isoferritins, and its application to serum ferritin evaluation
WO2007008966A1 (fr) Dosage elisa pour détecter des formes multimériques d'une protéine
JP3124028B2 (ja) 還元的にグリコシル化されたｎ―末端アミノ酸に向けられた抗原を使用するグリコシル化されたタンパクの免疫学的測定法
JP3490715B2 (ja) ヘモグロビン前進性グルコシル化終末産物の検出方法
Chapelle et al. Automated quantification of creatine kinase MB isoenzyme in serum by radial partition immunoassay, with use of the Stratus analyzer
Matikainen et al. Demonstration of the Predominant Urine Osteocalcin Fragments Detectable by Two‐Site Immunoassays
Saile et al. Quantification of serum amyloid P by enzyme-linked immunosorbent assay
JP3308027B2 (ja) 一又はそれより多い被分析物質の免疫学的測定のための診断方法
JP2762058B2 (ja) カルボニル化合物− タンパク質複合体の定量法
Tsutsumi et al. A new radioimmunoassay of free thyroxine using 125I-labelled thyroxine—protein complex uninfluenced by albumin and thyroxine-binding globulin
Harper et al. Protein A-bearing Staphylococcus aureus as the solid phase in an enzyme immunoassay and its application to determination of urinary albumin.
FR2596867A1 (fr) Procede immunologique de dosage de l'erythropoietine
WO2002008722A2 (fr) Evaluation directe de concentrations relatives de variants d'un epitope sur une molecule dimere

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997901090

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97525713

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1997901090

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997901090

Country of ref document: EP